Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial

Authors: Luca Richeldi, Evans R. Fernández Pérez, Ulrich Costabel, Carlo Albera, David J. Lederer, Kevin R. Flaherty, Neil Ettinger, Rafael L. Perez, Mary Beth Scholand, Jonathan Goldin, Kin-Hung P. Yu, Thomas B. Neff, Seth Porter, Ming Zhong, Eduard Gorina, Elias Kouchakji, Ganesh Raghu - The Lancet 2019 cited by 286